跳至主要内容
临床试验/NCT01190072
NCT01190072终止不适用

LIPID-LOWERING THERAPY FOR SECONDARY PREVENTION IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) A 10-week, Open-label, Non-interventional Study of Total Cholesterol/LDL-cholesterol Management in Real Life in Coronary Patients Hospitalised for Elective PCI

AstraZeneca1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2010年9月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
AstraZeneca
入组人数
120
试验地点
1
主要终点
Serum total cholesterol concentration

研究概览

简要总结

The purpose of the study is to follow the management of blood lipids in patients with planned percutaneous coronary intervention (widening of coronary vessels) in a period from 6 to 10 weeks after the intervention.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or nonpregnant female
  • Coronary patient hospitalised for elective PCI
  • Hypercholesterolaemia defined as LDL-C ≥ 2 mmol/L

排除标准

  • Any chronic inflammatory condition
  • Chronic anti-inflammatory pharmacotherapy (except low-dose ASA)

结局指标

主要结局

Serum total cholesterol concentration

时间窗: Once during the time period between Week 6 and Week 10

Serum LDL cholesterol concentration

时间窗: Once during the time period between Week 6 and Week 10

次要结局

  • Proportion of patients achieving LDL-C < 2 mmol/L(Once during the time period between Week 6 and Week 10)
  • Proportion of patients achieving total cholesterol < 4 mmol/L(Once during the time period between Week 6 and Week 10)
  • Change of hsCRP levels from baseline(Once during the time period between Week 6 and Week 10)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验